Looking Into Eli Lilly's Recent Short Interest
Rhythm Pharma Draws Bullish View at JMP on Opportunity in Rare Genetic Obesities
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
Unpacking the Latest Options Trading Trends in Eli Lilly
BioNTech Raised to Buy at Jefferies on New Cancer Drug
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Tuesday Ahead of US FOMC Policy Meeting
BeyondSpring Plinabulin, Merck Keytruda Combo Shows Promise in NSCLC
What the Options Market Tells Us About UnitedHealth Group
A Closer Look at 8 Analyst Recommendations For Merck & Co
CG Oncology Surges 7%; Seen Benefitting From J&J Bladder Cancer Asset Data
Cantor Fitzgerald Reiterates Overweight on Merck & Co, Maintains $155 Price Target
Merck & Co Analyst Ratings
Eli Lilly Analyst Ratings
Moderna Was Most Shorted S&P 500 Healthcare Stock in August for Second Consecutive Month
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
Johnson & Johnson Analyst Ratings
Immutep's Efti In Combination With MSD's KEYTRUDA Leads To Efficacy With Favourable Safety In First Line Head And Neck Cancer
Thermo Fisher Scientific Analyst Ratings
Reported Saturday, Johnson & Johnson Shares New Data on RYBREVANT in Metastatic Colorectal Cancer at ESMO Congress
Reported Sunday, Johnson & Johnson Reveals New Data on TAR-200 for Bladder Cancer Treatment